PL2402032T3 - Kompozycja immunogenna - Google Patents

Kompozycja immunogenna

Info

Publication number
PL2402032T3
PL2402032T3 PL10746311T PL10746311T PL2402032T3 PL 2402032 T3 PL2402032 T3 PL 2402032T3 PL 10746311 T PL10746311 T PL 10746311T PL 10746311 T PL10746311 T PL 10746311T PL 2402032 T3 PL2402032 T3 PL 2402032T3
Authority
PL
Poland
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
PL10746311T
Other languages
English (en)
Inventor
Reiji Nishio
Nobuo Ida
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Publication of PL2402032T3 publication Critical patent/PL2402032T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10746311T 2009-02-27 2010-02-26 Kompozycja immunogenna PL2402032T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009045555 2009-02-27
EP10746311.9A EP2402032B1 (en) 2009-02-27 2010-02-26 Immunogenic composition
PCT/JP2010/053055 WO2010098432A1 (ja) 2009-02-27 2010-02-26 免疫原性組成物

Publications (1)

Publication Number Publication Date
PL2402032T3 true PL2402032T3 (pl) 2020-03-31

Family

ID=42665636

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10746311T PL2402032T3 (pl) 2009-02-27 2010-02-26 Kompozycja immunogenna

Country Status (15)

Country Link
US (1) US9056095B2 (pl)
EP (1) EP2402032B1 (pl)
JP (1) JP6008345B2 (pl)
KR (1) KR20110128284A (pl)
CN (1) CN102333541B (pl)
AU (1) AU2010218752B2 (pl)
BR (1) BRPI1005919B1 (pl)
CA (1) CA2753567C (pl)
DK (1) DK2402032T3 (pl)
ES (1) ES2755361T3 (pl)
HU (1) HUE046865T2 (pl)
MX (1) MX2011008923A (pl)
PL (1) PL2402032T3 (pl)
PT (1) PT2402032T (pl)
WO (1) WO2010098432A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
AU2011294244B2 (en) * 2010-08-26 2014-06-12 Toray Industries, Inc. Immunogenic composition
WO2013085021A1 (ja) * 2011-12-09 2013-06-13 株式会社林原 抗体産生増強用の組成物
MX375442B (es) 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
CN102988981B (zh) * 2012-12-13 2015-03-04 中国水产科学研究院黄海水产研究所 一种增强爱德华氏菌疫苗免疫接种效果的佐剂及使用方法
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
KR102343005B1 (ko) 2013-10-09 2021-12-24 도레이 카부시키가이샤 면역 부활화제
US10293044B2 (en) 2014-04-18 2019-05-21 Auburn University Particulate formulations for improving feed conversion rate in a subject
ES2782428T3 (es) * 2014-04-18 2020-09-15 Univ Auburn Formulaciones vacunales de partículas para la inducción de inmunidad innata y adaptativa
MX391930B (es) 2015-01-16 2025-03-21 Zoetis Services Llc Vacuna contra la fiebre aftosa.
GB201918963D0 (en) 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants
JPWO2023032892A1 (pl) 2021-08-30 2023-03-09
KR20240054289A (ko) 2021-08-30 2024-04-25 도레이 카부시키가이샤 면역원성 증강용 조성물
EP4403182A4 (en) * 2021-09-16 2025-12-24 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2600085A1 (en) 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticle and pharmaceutical preparation
JP2008088158A (ja) 2006-09-05 2008-04-17 Toray Ind Inc 親水性活性物質含有微粒子の製造方法
JP2008254338A (ja) 2007-04-05 2008-10-23 Bridgestone Corp タイヤの製造方法およびその装置
DK2862876T3 (en) 2008-09-30 2016-05-23 Toray Industries Antibody binding to envelope protein 2 of hepatitis C virus and method for identifying the genotype of hepatitis C virus using the same

Also Published As

Publication number Publication date
PT2402032T (pt) 2019-11-19
EP2402032A1 (en) 2012-01-04
AU2010218752A1 (en) 2011-08-25
JP6008345B2 (ja) 2016-10-19
EP2402032A4 (en) 2013-05-01
US9056095B2 (en) 2015-06-16
BRPI1005919A2 (pt) 2016-02-10
CN102333541A (zh) 2012-01-25
MX2011008923A (es) 2011-09-09
CA2753567C (en) 2019-12-31
CN102333541B (zh) 2014-09-03
WO2010098432A1 (ja) 2010-09-02
CA2753567A1 (en) 2010-09-02
EP2402032B1 (en) 2019-08-14
ES2755361T3 (es) 2020-04-22
HUE046865T2 (hu) 2020-03-30
JPWO2010098432A1 (ja) 2012-09-06
US20110300223A1 (en) 2011-12-08
BRPI1005919B1 (pt) 2021-06-22
KR20110128284A (ko) 2011-11-29
AU2010218752B2 (en) 2015-05-28
DK2402032T3 (da) 2019-11-04

Similar Documents

Publication Publication Date Title
GB0913681D0 (en) Immunogenic composition
GB201003924D0 (en) Immunogenic composition
GB0908129D0 (en) Composition
GB0918450D0 (en) Composition
IL217949A0 (en) Pesticdal compositions
GB0911428D0 (en) Composition
HUE046865T2 (hu) Immunogén készítmény
ZA201107839B (en) Composition
IL242592A (en) Immunogenic compounds
ZA201107838B (en) Composition
GB0909362D0 (en) Composition
IL214127A0 (en) Vaccine compositions
PL2393887T3 (pl) Kompozycja
GB0906779D0 (en) Composition
GB0904941D0 (en) Composition
GB0904942D0 (en) Composition
GB0913680D0 (en) Immunogenic composition
GB0922389D0 (en) composition
IL220308A0 (en) Vaccine compositions
GB201006350D0 (en) Composition
GB0911294D0 (en) Composition
GB0918590D0 (en) Composition
GB0903688D0 (en) Composition
GB0922133D0 (en) Composition
GB0902959D0 (en) Composition